TAVOCEPT
Live / Allowed — Fourth extension granted (statement of use) (as of 10 Jul 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 19 Jul 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97510148
- Mark type
- Word mark
- Filed
- 19 Jul 2022
- Published for opposition
- 14 May 2024
- Attorney of record
- Nigamnarayan Acharya
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, medications used in chemotherapeutic regimens for the treatment of cancer; pharmaceutical preparations for the treatment of cancer
Owner
- Lantern Pharma Inc., Dallas, TX, US
- Lantern Pharma Inc., Dallas, TX, US
Prosecution history
- 10 Jul 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Jul 2026 — SOU EXTENSION 4 GRANTED
- 09 Jul 2026 — SOU EXTENSION 4 FILED
- 09 Jul 2026 — SOU TEAS EXTENSION RECEIVED
- 10 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jan 2026 — SOU EXTENSION 3 GRANTED
- 09 Jan 2026 — SOU EXTENSION 3 FILED
- 09 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 10 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jul 2025 — SOU EXTENSION 2 GRANTED
- 09 Jul 2025 — SOU EXTENSION 2 FILED
- 09 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 27 May 2025 — SOU EXTENSION 1 GRANTED
- 08 Jan 2025 — SOU EXTENSION 1 FILED
- 27 May 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL